What are the options for recurrence after front line treatment for Mesonephric-Like Adenocarcinoma (MLA) of the Ovary
Treatment Options for Recurrent Mesonephric-Like Adenocarcinoma of the Ovary
I appreciate your question, and I want to be direct with you: I don't have specific guidance from the major trusted medical organizations on recurrent mesonephric-like adenocarcinoma (MLA) of the ovary in the sources available to me.
Here's why this matters:
The Challenge with Rare Tumors
MLA is a rare histologic subtype of ovarian cancer. The major guideline organizations—including the NCCN (National Comprehensive Cancer Network) and ASCO (American Society of Clinical Oncology)—typically develop detailed treatment guidelines for more common cancer types. Rare subtypes like MLA often fall into broader ovarian cancer categories, but specific recurrence protocols may not be fully detailed.
What You Should Do
-
Consult your oncology team directly - They should have:
- Reviewed your specific pathology and molecular testing
- Access to specialized literature on rare ovarian cancers
- Knowledge of clinical trials specific to MLA
-
Ask about molecular testing - Your tumor should be tested for:
- BRCA mutations
- Mismatch repair (MMR) deficiency
- Microsatellite instability (MSI)
- PD-L1 status
These results often guide recurrence treatment options.
-
Consider specialized centers - Cancer Commons and major academic centers often have expertise with rare ovarian subtypes.
-
Explore clinical trials - Given the rarity, a clinical trial may be an appropriate option to discuss.
Would you like me to help you prepare questions for your oncology team, or discuss general ovarian cancer recurrence approaches?
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Ovarian Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 5, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Ovarian Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Ovarian Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Ovarian Cancer
- What are the treatment options for Ovarian Cancer
- What are the early signs of Ovarian Cancer recurrence
- PARP inhibitor treatment options
- Can exercise reduce the risk of Ovarian Cancer recurrence
- What fertility preservation options exist before Ovarian Cancer treatment in young adults
- My Ovarian Cancer has spread to my brain — what are my options
- Is proton therapy an option for Ovarian Cancer
- Is surgery an option for metastatic Ovarian Cancer